RAMSELPHARMA

RAMSELPHARMA has been active since 1991 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €637,252 and a net result of €124,952. Equity remains stable across the filed financial years (±0.2% per year). Its solvency ranks better than 80% of 12,650 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).